armodafinil

(-)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide

The R-enantiomer of the racemic synthetic agent modafinil with central nervous system (CNS) stimulant and wakefulness-promoting activities. Although the exact mechanism of action has yet to be fully elucidated, armodafinil appears to inhibit the reuptake of dopamine by binding to the dopamine-reuptake pump, which leads to an increase in extracellular dopamine levels in some brain regions. This agent does not bind to or inhibit several receptors and enzymes that may be involved in sleep/wake regulation and is not a direct- or indirect-acting dopamine receptor agonist. Armodafinil has a longer half-life than modafinil. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C65241" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C65241" NCI Thesaurus)

http://purl.bioontology.org/ontology/PDQ/CDR0000617902

(-)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide

Nuvigil

C1871544

C1701455

2008-10-17

2010-02-18

The R-enantiomer of the racemic synthetic agent modafinil with central nervous system (CNS) stimulant and wakefulness-promoting activities. Although the exact mechanism of action has yet to be fully elucidated, armodafinil appears to inhibit the reuptake of dopamine by binding to the dopamine-reuptake pump, which leads to an increase in extracellular dopamine levels in some brain regions. This agent does not bind to or inhibit several receptors and enzymes that may be involved in sleep/wake regulation and is not a direct- or indirect-acting dopamine receptor agonist. Armodafinil has a longer half-life than modafinil. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C65241" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C65241" NCI Thesaurus)

TRD

C65241

CDR0000617902

Drug/agent

armodafinil

T109

T121